NCT03370198View on ClinicalTrials.gov

Hepatic Transarterial Administrations of NKR-2 in Patients With Unresectable Liver Metastases From Colorectal Cancer

PHASE1TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

October 11, 2017

Primary Completion Date

January 15, 2018

Study Completion Date

December 15, 2018

Conditions
Colon Cancer Liver Metastasis
Interventions
BIOLOGICAL

NKR-2 cells

NKR-2 cells will be administered (hepatic transarterial administration) every 2 weeks (14 days) for a total of 3 administrations within 4 weeks (28 days)

Trial Locations (1)

1000

Institut Jules Bordet, Brussels

Sponsors

Lead Sponsor

Celyad Oncology SA
All Listed Sponsors
lead

Celyad Oncology SA

INDUSTRY

NCT03370198 - Hepatic Transarterial Administrations of NKR-2 in Patients With Unresectable Liver Metastases From Colorectal Cancer | Biotech Hunter | Biotech Hunter